This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novozymes, Chr. Hansen win EU merger approval, with divestiture of upcoming lactase project (update*)

By Andrew Boyce ( December 12, 2023, 15:30 GMT | Insight) -- Novozymes and rival Danish enzyme maker Chr. Hansen have won EU approval for their merger, after agreeing to divest assets including plans by Chr. Hansen to start manufacturing lactase. The European Commission was concerned the merger would harm competition in the lactase market as Chr. Hansen’s project would likely have turned it into an “effective competitor” to Novozymes within “a short timeframe.”Novozymes and rival Danish enzyme maker Chr. Hansen have won EU approval for their merger, after agreeing to divest assets including plans by Chr. Hansen to start manufacturing lactase....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login